{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44","upperLimit":"69.2","value":"56.9"},{"groupId":"OG001","lowerLimit":"3.4","upperLimit":"39.6","value":"15.8"},{"groupId":"OG002","lowerLimit":"0.1","upperLimit":"14.2","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"description":"CR rate, defined as the percentage of patients who achieved CR+ CR with minimal residual skin abnormality (CRc) after treatment with Tagraxofusp.\n\nCR criteria according to Cheson BD et al, The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586:\n\nMarrow: normalization of blast percentage (≤5%)\n\nPeripheral blood: normalization of neutrophil count (≥ 1,000/µL) and platelet count (≥ 100,000/µL) - absence of leukemic blasts\n\nSkin: 100% clearance of all skin lesions from baseline; no new lesions in patients without lesions at baseline\n\nNodal masses: regression to normal size on CT\n\nSpleen, liver: not palpable, nodules disappeared\n\nCRc criteria: all the above except for skin: marked clearance of all skin lesions from baseline; residual hyperpigmentation or abnormality with BPDCN identified on biopsy (or no biopsy performed)","dispersionType":"95% Confidence Interval","groups":[{"description":"First-Line BPDCN patients enrolled across stages","id":"OG000","title":"First-line BPDCN"},{"description":"R/R BPDCN patients enrolled across stages","id":"OG001","title":"R/R BPDCN"},{"description":"AML patients enrolled in stage 1-2","id":"OG002","title":"Acute Myeloid Leukemia"}],"paramType":"NUMBER","populationDescription":"Efficacy population including evaluable patients treated at 12 μg/kg/day in the first-line BPDCN, R/R BPDCN and AML.","reportingStatus":"POSTED","timeFrame":"at pre-defined treatment cycle intervals from randomization up to disease progression, up to 5 years","title":"CR Rate in First-line BPDCN, R/R BPDCN and AML","type":"SECONDARY","unitOfMeasure":"percentage of evaluable patients"}